Under construction – not a live service
Sign in
Not yet taking people in ChinaPhase 3

Tenecteplase Given Through an Artery for Stroke Caused by a Blocked Medium-Sized Vessel

Tests tenecteplase delivered into an artery in adults with ischemic stroke.

Plain-language title generated from the registry record
Registry title: Efficacy and Safety of Intra-arterial Tenecteplase in Acute Ischemic Stroke Patients With Medium Vessel Occlusion Stroke (DATE-MeVO)

Key facts

Where
Ankang, Anyang, Baise City, Changchun, Chengdu, Chongqing, Dali, Fuzhou, Guangyuan, Guilin, Guizhou, Huaibei, Jianyang, Jinan, Luoyang, Luzhou, Mianyang, Mudanjiang, Qiannan, Qingzhen, Qujing, Sanmenxia, Shangqiu, Suining, Tangshan, Wuhan, Xiangyang, Ya'an, Yichang, Zhengzhou, Zhoukou, Zhumadian, Zhuzhou, and Zigong, ChinaSee the 45 sites
Phase
Phase 3

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a stroke caused by a blocked medium-sized brain artery, within 24 hours of the first symptoms. It tests tenecteplase given in the artery together with standard medicines.

Age
18 to 100 years
Sex
All sexes can join.
Disease stage
Sudden stroke from a blocked medium-sized brain artery, confirmed by imaging, with symptoms starting within 24 hours. NIHSS score of 5 or more. CT scan shows no early large area of damage. Before the stroke, mRS score was 0 or 1.
Earlier treatment
People who already had thrombolysis through a vein cannot join. People for whom a mechanical clot removal procedure is planned cannot join.

Main reasons for not taking part

  • Bleeding in the brain seen on CT or MRI
  • Pregnant or breastfeeding women
  • Bleeding disorder, high INR, or blood thinner tablets taken within 48 hours
  • Chronic dialysis or severe kidney problems
  • Blood pressure that stays above 185/110 mmHg despite tablets

Read by machine on 12 November 2026.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 100 years old?

Source: NCT07469293, who can take part

Where in China

  • Ankang Central HospitalAnkang, ChinaContact: Chu XingjvNo longer taking part
  • The People's Hospital of Anyang CityAnyang, ChinaContact: Zhang JiangangNo longer taking part
  • Affiliated Hospital of Youjiang Medical University for NationalitiesBaise City, ChinaContact: Xianhua HouNo longer taking part
  • Changchun Central HospitalChangchun, ChinaContact: Wang LeshengNo longer taking part
  • Chengdu Second People's HospitalChengdu, ChinaContact: Wu ChangchuanNo longer taking part
  • Chongzhou People's HospitalChengdu, ChinaContact: Wu YoulinNo longer taking part
  • Chonggang General HospitalChongqing, ChinaContact: Ding ChawenNo longer taking part
  • Chongqing University Fuling HospitalChongqing, ChinaContact: Xianhua HouNo longer taking part
  • Jiangjin Central HospitalChongqing, ChinaContact: Zhang ZuowenNo longer taking part
  • The Ninth People'S Hospital of ChongqingChongqing, ChinaContact: Huang ShuchunNo longer taking part
  • The Thrid Affiliated Hospital of CQMUChongqing, ChinaContact: Cheng SaiyuNo longer taking part
  • Yunyang County People's HospitalChongqing, ChinaContact: Cai TieyingNo longer taking part
  • Dali Nationality Autonomous Prefecture HospitalDali, ChinaContact: Han ShiboNo longer taking part
  • The First Affiliated Hospital of Fujian MedicaluniversityFuzhou, ChinaContact: Zhao WenlongNo longer taking part
  • Guangyuan Central HospitalGuangyuan, ChinaContact: Pu TianqiangNo longer taking part
  • Guilin People's HospitalGuilin, ChinaContact: Pan HonghuaNo longer taking part
  • Qiandongnan Prefecture People's HospitalGuizhou, ChinaContact: Shen JianNo longer taking part
  • Huaibei Miners General HospitalHuaibei, ChinaContact: Ma XinanNo longer taking part
  • The People's Hospital of Jianyang CityJianyang, ChinaContact: Tang JieNo longer taking part
  • The 960th Hospital of the PLA Joint Logistics Support ForceJinan, ChinaContact: Xianhua HouNo longer taking part
  • Luoyang Mengjin People's HospitalLuoyang, ChinaContact: Zhao HaojinNo longer taking part
  • The First Affiliated Hospital of Henan University of Science and TechnologyLuoyang, ChinaContact: Shen RuileNo longer taking part
  • Yiyang County People's HospitalLuoyang, ChinaContact: Zhao JingjingNo longer taking part
  • The Affiliated Hospital of Southwest Medical UniversityLuzhou, ChinaContact: Yuan ZhengzhouNo longer taking part
  • The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical UniversityLuzhou, ChinaContact: Guo ZhaoyunNo longer taking part
  • Mianyang 404 HospitalMianyang, ChinaContact: Luo JunNo longer taking part
  • Mudanjiang First People's HospitalMudanjiang, ChinaContact: Yu PengfeiNo longer taking part
  • The People's Hospital Of QianNanQiannan, ChinaContact: Jiang MaojunNo longer taking part
  • The First People's Hospital of QingzhenQingzhen, ChinaContact: Fu HangNo longer taking part
  • Qujing Central Hospital of Yunnan ProvinceQujing, ChinaContact: Chen BoyuNo longer taking part
  • Yellow River Sanmenxia HospitalSanmenxia, ChinaContact: Wu XiaofengNo longer taking part
  • Ninglin People's HospitalShangqiu, ChinaContact: Ju ZhixiangNo longer taking part
  • The First People's Hospital of ShangqiuShangqiu, ChinaContact: Xianhua HouNo longer taking part
  • The People's Hospital Of An JvSuining, ChinaContact: Liao JiashengNo longer taking part
  • Yutian HospitalTangshan, ChinaContact: Li HaijunNo longer taking part
  • Wuhan Puren HospitalWuhan, ChinaContact: Xianhua HouNo longer taking part
  • Zhongnan Hospital of Wuhan UniversityWuhan, ChinaContact: Mei BinNo longer taking part
  • Xiangyang No.1 People's HospitalXiangyang, ChinaContact: Zhou PeiyangNo longer taking part
  • Yaan People's HospitalYa'an, ChinaContact: Wang JianNo longer taking part
  • Yichang Central People's HospitalYichang, ChinaContact: Zhou JinghuaNo longer taking part
  • Zhengzhou Central HospitalZhengzhou, ChinaContact: Zhou YouNo longer taking part
  • Zhoukou Central HospitalZhoukou, ChinaContact: Li ShuaiNo longer taking part
  • Zhumadian Central HospitalZhumadian, ChinaContact: Xianhua HouNo longer taking part
  • Zhuzhou Central HospitalZhuzhou, ChinaContact: Xianhua HouNo longer taking part
  • Zigong Third People's HospitalZigong, ChinaContact: Xianhua HouNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Southwest Hospital, China
Trial code
NCT07469293
Record updated
20 March 2026
Original description
DATE-MeVO is an investigator-initiated, multicenter, prospective, randomized controlled, open-label, blinded endpoint (PROBE) clinical trial aiming at evaluating the efficacy and safety of tenecteplase combined with standard medications in acute ischemic stroke patients with medium vessel occlusion stroke within 24 hours of onset.Read full original descriptionShow less

Efficacy and Safety of Intra-arterial Tenecteplase in Acute Ischemic Stroke Patients With Medium Vessel Occlusion Stroke (DATE-MeVO): A Multicenter, Prospective, Randomized Controlled, Open-label, Blinded-Endpoint Clinical Trial

DATE-MeVO is an investigator-initiated, multicenter, prospective, randomized controlled, open-label, blinded endpoint (PROBE) clinical trial aiming at evaluating the efficacy and safety of tenecteplase combined with standard medications in acute ischemic stroke patients with medium vessel occlusion stroke within 24 hours of onset.

Inclusion: Age ≥18 years old; Acute isolated intracranial medium vessel occlusion (Distal middle cerebral artery M2; M3 and M4 segments of the middle cerebral artery; A1-A4 segments of the anterior cerebral artery; P1-P3 segments of the posterior cerebral artery), confirmed by imaging, with symptom onset to randomization within 24 hours; NlHSS score ≥ 5; CT scan performed within 24 hours confirming that the ischemic lesion does not involve more than one-third of the territory supplied by the responsible vessel (no evidence of early large infarction); Patients with premorbid mRS 0 or 1; Written informed consent obtained from the participant or a legally authorized representative.

Exclusion: Already received intravenous thrombolysis; Concurrent malignant tumors or severe systemic diseases with an expected survival time of less than 90 days; Participation in another clinical interventional trial within 30 days prior to randomization or currently participating in another clinical interventional trial; Intracranial hemorrhage confirmed by cranial CT or MRI; Allergy to contrast agents or tenecteplase; Systolic blood pressure > 185 mmHg or diastolic blood pressure > 110 mmHg, and failure to control with oral antihypertensive medications; History of bleeding within the past month (gastrointestinal or urinary tract bleeding); Severe mental disorders or inability to provide informed consent and comply with follow-up due to dementia; Genetic or acquired bleeding disorders, coagulation factor deficiencies; coagulation dysfunction, INR > 1.7, or use of novel oral anticoagulants within 48 hours; Blood glucose < 2.8 mmol/L (50 mg/dL) or > 22.2 mmol/L (400 mg/dL), platelet count < 100 × 10\^9/L; Chronic hemodialysis or severe renal insufficiency (glomerular filtration rate < 30 mL/min or serum creatinine > 220 μmol/L (2.5 mg/dL)); Planned mechanical thrombectomy; Intraoperative DSA showing vessel rupture, dissection, or contrast agent extravasation; Pregnant or breastfeeding women; Intracranial aneurysms or arteriovenous malformations; Occlusions in multiple vascular territories confirmed by CTA/MRA; Other reasons that the investigator deems inappropriate for participation in the trial.

ClinicalTrials.gov NCT07469293